Full Press Release Details
Phase 2 clinical data on the efficacy of D-PLEX100 in surgical site infection prevention in elective colorectal surgery will be presented during a poster presentation
PETACH TIKVA, Israel, June 06, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that data from a previously completed Phase 2 clinical trial of D-PLEX100 will be highlighted in a presentation at the upcoming American Microbiology Society (ASM) Microbe 2022, being held on June 9-13, 2022, in Washington, D.C.
The abstract, ‘Incisional microenvironments and reduction in SSIs in patients treated with a local doxycycline-eluting formulation,’ evaluates the effect of D-PLEX100 in combination with surgical site infection standard of care prophylaxis regimen in elective colorectal surgery. The data will be presented by Judith Steenbergen, Ph.D., President of Scientific and Medical Affairs Consulting (SMAC). The abstract will be available on https://www.polypid.com/ following the presentation.
References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.
Dikla Czaczkes Akselbrad